SCHEMBL1194433

SCHEMBL1194433

O=S(=O)(/C=C\c1ccc(F)cc1)Cc1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 1/20 0.51
PKM P14618 1/20 0.42
HTR2A P28223 2/20 0.41
KCNH2 Q12809 2/20 0.41
HSD11B1 P28845 1/20 0.41
NFE2L2 Q16236 2/20 0.41
GPR183 P32249 2/20 0.40
PTGS1 P23219 1/20 0.40
FBP1 P09467 1/20 0.39
TNFRSF1A P19438 1/20 0.38
CYP2D6 P10635 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1194500 1.00 KMT2A (0.51) KMT2AMEN1PKMHTR2AKCNH2
SCHEMBL1194436 1.00 KMT2A (0.51) KMT2AMEN1PKMHTR2AKCNH2
SCHEMBL3678125 0.92 KMT2A (0.46) KMT2AMEN1PKMHTR2AKCNH2
SCHEMBL1194573 0.92 KMT2A (0.46) KMT2AMEN1PKMHTR2AKCNH2
SCHEMBL827908 0.92 MEN1 (0.46) KMT2AMEN1NFE2L2GPR183MAPT
SCHEMBL6550137 0.92 KMT2A (0.46) KMT2AMEN1PKMHTR2AKCNH2
SCHEMBL5871973 0.92 KMT2A (0.46) KMT2AMEN1PKMHTR2AKCNH2
SCHEMBL1195026 0.92 KMT2A (0.63) KMT2AMEN1NFE2L2GPR183PTGS1
SCHEMBL1194446 0.92 KMT2A (0.63) KMT2AMEN1NFE2L2GPR183PTGS1
SCHEMBL1194779 0.92 MEN1 (0.46) KMT2AMEN1NFE2L2GPR183MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1180024-B1 Z-STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2004-02-04 EP claimed
US-6414034-B1 ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-07-02 US claimed
EP-1180024-A4 Z-STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2002-06-19 EP claimed
EP-1180024-A1 Z-STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2002-02-20 EP claimed
US-6201154-B1 Z-styryl sulfone anticancer agents TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION 2001-03-13 US claimed
WO-2000057872-A1 Z-STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-05 WO claimed
US-20150238448-A1 FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES ONCONOVA THERAPEUTICS, INC (US) 2015-08-27 US disclosed
EP-2769719-A1 Formulations of radioprotective alpha, beta unsaturated aryl sulfones Onconova Therapeutics, Inc. (US) 2014-08-27 EP disclosed
EP-2046343-B1 FORMULATIONS OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES ONCONOVA THERAPEUTICS INC (US) 2014-05-14 EP disclosed
EP-1909775-B1 FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES ONCONOVA THERAPEUTICS INC (US) 2012-05-16 EP disclosed
US-20110028504-A1 Formulation of radioprotective alpha beta unsaturated aryl sulfones ONCONOVA THERAPEUTICS, INC. (US) 2011-02-03 US disclosed
EP-1223923-B1 UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS UNIV TEMPLE (US) 2010-03-31 EP disclosed
US-20090247624-A1 FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES ONCONOVA THERAPEUTICS INC. (US) 2009-10-01 US disclosed
EP-1223923-A1 METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS Temple University of the Commonwealth System of Higher Education (US) 2002-07-24 EP disclosed
US-6414034-B1 ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-07-02 US disclosed
EP-1180024-A4 Z-STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2002-06-19 EP disclosed
EP-1180024-A1 Z-STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2002-02-20 EP disclosed
WO-2001026645-A1 METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2001-04-19 WO disclosed
US-6201154-B1 Z-styryl sulfone anticancer agents TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION 2001-03-13 US disclosed
WO-2000057872-A1 Z-STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247624-A1 FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES ARSA, DEGS1, AHR KMT2A 3985/4885MEN1 3782/4885PKM 3517/4885
US-20150238448-A1 FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES ARSA, AHR, SULT2A1 KMT2A 3678/4885MEN1 3963/4885PKM 3291/4885
US-20110028504-A1 Formulation of radioprotective alpha beta unsaturated aryl sulfones DEGS1, ARSA, ABCE1 KMT2A 4426/4885MEN1 4017/4885PKM 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.